Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The record history now shows additional submission versions, expanding the list of past updates. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-03T12:38:36.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    29 days ago
    Change Detected
    Summary
    Major update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.
    Difference
    8%
    Check dated 2025-10-05T17:37:45.000Z thumbnail image
  4. Check
    36 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0; no other content changes detected.
    Difference
    0.2%
    Check dated 2025-09-28T11:17:50.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    Page revision updated from v3.0.1 to v3.0.2; the 'Back to Top' element has been removed.
    Difference
    0.5%
    Check dated 2025-09-14T00:53:17.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new revision version (v3.0.1) and includes a new date (2025-09-05) while removing the previous revision date (2025-08-26).
    Difference
    1%
    Check dated 2025-09-06T21:28:09.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The web page has been updated to include a new facility name and location, along with a significant number of study status updates and dates, while some location-related terms have been removed.
    Difference
    76%
    Check dated 2025-08-30T15:57:29.000Z thumbnail image

Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.